Search

  • Sorting

  • Filter

Found 602 Results
Page 2 of 61

ADC analytics FAQs: Answering the most common questions about ADC characterization


Antibody-drug conjugates (ADCs) have emerged as one of the fastest-growing classes of biotherapeutics, combining the targeting specificity of monoclonal antibodies with the potency of cytotoxic payloads. However, this unique architecture also introduces significant analytical complexity. From drug-to-antibody ratio (DAR) distributions and charge variants to conjugation sites and structural modifications, ADCs present multiple, interconnected sources of heterogeneity that must be understood to ensure product quality and performance.

Tags: , , , , , , , , , , , , , , , , , , ,

August 14, 2026


Sterile but toxic: Cereulide detection in food matrices


In a recent webinar, Ming Gao, Ph.D., Senior Research Chemist at Mérieux NutriSciences, explored the growing challenge of cereulide contamination in food products and the analytical strategies needed to detect this heat-stable toxin at trace levels. The session examined how LC-MS/MS can help laboratories overcome the limitations of traditional microbiological screening and meet emerging regulatory requirements.

Tags: , , , , , , , , , , , , , , , , , , ,

August 4, 2026


How SCIEX Now empowers mass spec users to work with more control, clarity and confidence


In this interview, Andy Wilcox, Senior Market Development Manager, Aftermarket and Software, speaks with Susanna Baqué, Senior Director of Global Customer Experience, about how SCIEX Now gives customers one connected digital workspace to manage instruments, reduce time spent searching for information, resolve issues faster and keep their laboratory running more efficiently and with greater confidence.

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

July 28, 2026


Bioanalysis across modalities: Advancing confident decisions with modern LC‑MS strategies


As therapeutic pipelines continue to diversify, bioanalysis is being asked to do more than ever before. From small molecules to complex biologics, today’s scientists must generate high‑quality, reliable data across a growing range of molecule types and workflows, often under increasing time pressure.

Tags: , ,

July 22, 2026


The rules have changed


Regulated laboratories are evolving faster than ever. New analytical modalities, higher sample throughput, increasing regulatory scrutiny, and leaner teams are reshaping how work gets done. At the same time, expectations for data integrity, standardization, and operational efficiency continue to increase complexity and/or scope. In this environment, LC-MS software is no longer simply an instrument control platform—it has become a critical part of a laboratory’s quality management system. The question is no longer whether your lab has changed, but whether your software has evolved to support the way regulated labs operate today, and if they are ready and able to meet the demands, they will face tomorrow.

Tags: , ,

July 10, 2026


The wakeup call


Analyst software has long been a trusted foundation in regulated LC-MS laboratories—and for many, it still performs reliably today. But regulated environments are evolving faster than ever. As labs transition to Windows 11, strengthen cybersecurity policies, modernize IT infrastructure, and prepare for future compliance expectations, software decisions are no longer just about what works today—they’re about managing tomorrow’s risk. Analyst will not be supported on Windows 11. While some labs may continue operating in unsupported environments temporarily, the bigger question is: when that risk becomes reality, will your lab be reacting under pressure—or executing a planned mitigation strategy with confidence?

Tags: , ,


Why TFA in water Is gaining attention, and how labs can measure it with confidence


As regulatory scrutiny increases and detection requirements tighten, laboratories are facing a new question:
How can TFA be measured reliably, sensitively, and at scale?

Tags: , , , , ,

July 2, 2026


Confident glycan characterization with EAD‑enabled LC‑MS workflows


Glycosylation is one of the more structurally diverse and biologically impactful PTMs in protein therapeutics. Both N‑linked and O‑linked glycans influence protein folding, stability, and biological activity. Given these effects on biotherapeutics, glycosylation is a closely monitored critical quality attribute (CQA). Comprehensive and site‑specific characterization of glycosylation is essential for informed decision‑making throughout drug discovery and development.

Tags: ,

June 30, 2026


7 risks every lab should consider before the warranty ends


Warranty expiration is more than an administrative milestone—it is a transition point that can significantly impact instrument uptime, laboratory productivity, operating budgets, and scientific outcomes.

Tags: , , , , , , , , ,

June 24, 2026


Accelerating Echo® MS system optimization with LeadScape®


For more than 20 years, the CDCO has supported academic, commercial, and not‑for‑profit drug discovery programs with deep expertise in pharmaceutical lead optimization. Within the bioanalytical group, their role is to enable rapid and reliable decision‑making through quantitative analysis of candidate drugs in biological matrices.

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , ,

June 17, 2026


Page 2 of 61

Pin It on Pinterest